Genetic tests are currently being offered to the general public with little oversight and regulation as to which tests are allowed to be sold clinically and little control over the marketing and promotion of sales and use. This article provides discussion and data to indicate that the general public holds high opinions of genetic testing and that current media outlets for public education on genetic testing are not adequate to increase accurate knowledge of genetics. The authors argue that more regulation is needed to control and correct this problem in the United States.
Ariail, K., Watts, C., & Bowen, D. (2005). Retention in a breast cancer risk information trial: Motivations of a population-based sample of women. Manuscript submitted for publication.
2.
Avorn, J., Chen, M., & Hartley, R. (1982). Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Journal of Medicine, 73(1), 4-8.
3.
Bowen, D., Burke, W., McTiernan, A., Powers, D., & Andersen, M. R. (2004). Breast cancer risk counseling improves women’s functioning. Patient Education & Counseling, 53(1), 79-86.
4.
Bowen, D. J., Ludman, E. J., Press, N., Vu, T., & Burke, W. (2003). Achieving utility with family history colorectal cancer risk. American Journal of Preventive Medicine, 24(2), 177-182.
5.
Bubela, T. M., & Caulfield, T. A. (2004). Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers. Canadian Medical Association Journal, 170(9), 1399-1407.
6.
Burke, W., Culver, J. O., Bowen, D., Lowry, D., Durfy, S., McTiernan, A., et al. (2000). Genetic counseling for women with an intermediate family history of breast cancer. American Journal of Medical Genetics, 90(5), 361-368.
7.
Caulfield, T., & Wertz, D. (2001). Creating needs? A review of survey data and concerns relevant to the commercialization of genetic testing. Community Genetics, 4(2), 68-76.
8.
Centers for Disease Control and Prevention. (2004). Genetic testing for breast and ovarian cancer susceptibility: Evaluating direct-to-consumer marketing—Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. Morbidity and Mortality Weekly Report, 53(27), 603-606.
9.
Cho, M. K., Arruda, M., & Holtzman, N. A. (1997). Educational material about genetic tests: Does it provide key information for patients and practitioners?American Journal of Medical Genetics, 73(3), 314-320.
10.
Condit, C. (2001). What is “public opinion” about genetics?Nature Reviews Genetics, 2(10), 811-815.
11.
Decruyenaere, M., Evers-Kiebooms, G., Denayer, L., & Welkenhuysen, M. (1998). Uptake and impact of carrier testing for cystic fibrosis. A review and a theoretical framework about the role of knowledge, health beliefs and coping. Community Genetics, 1(1), 23-35.
12.
Durfy, S. J., Bowen, D. J., McTiernan, A., Sporleder, J., & Burke, W. (1999). Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiology, Biomarkers & Prevention, 8(4, Pt 2), 369-375.
13.
Feuer, E. J., Wun, L. M., Boring, C. C., Flanders, W. D., Timmel, M. J., & Tong, T. (1993). The lifetime risk of developing breast cancer. Journal of the National Cancer Institute, 85(11), 892-897.
14.
Gollust, S. E., Hull, S. C., & Wilfond, B. S. (2002). Limitations of direct-to-consumer advertising for clinical genetic testing. Journal of the American Medical Association, 288(14), 1762-1767.
15.
Gollust, S. E., Wilfond, B. S., & Hull, S. C. (2003). Direct-to-consumer sales of genetic services on the Internet. Genetics in Medicine, 5(4), 332-337.
16.
Gray, S., & Olopade, O. I. (2003). Direct-to-consumer marketing of genetic tests for cancer: Buyer beware. Journal of Clinical Oncology, 21(17), 3191-3193.
17.
Green, M. J., Biesecker, B. B., McInerney, A. M., Mauger, D., & Fost, N. (2001). An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. American Journal of Medical Genetics, 103(1), 16-23.
18.
Gutknecht, D. R. (2001). Evidence-based advertising? A survey of four major journals. Journal of the American Board of Family Practice, 14(3), 197-200.
19.
Holtzman, N. A. (1999). Are genetic tests adequately regulated?Science, 286(5439), 409.
20.
Hull, S. C., & Prasad, K. (2001). Reading between the lines: Direct-to-consumer advertising of genetic testing. Hastings Center Report, 31(3), 33-35.
21.
Institute, N. C. (2002a). Breast cancer (pdq®): Prevention. Retrieved August 16, 2002, from http://cancer.gov/cancertopics/pdq/prevention/breast/healthprofessional
22.
Institute, N. C. (2002b). Breast cancer (pdq®): Screening. Retrieved August 16, 2002, from http://cancer.gov/cancertopics/pdq/screening/breast/healthprofessional
23.
Institute, N. C. (2002c). Genetics of breast and ovarian cancer (pdq®). Retrieved August 8, 2002, from http://cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional
24.
Javitt, G. H., Stanley, E., & Hudson, K. (2004). Direct-to-consumer genetic tests, government oversight, and the first amendment: What the government can (and can’t) do to protect the public’s health. Oklahoma Law Review, 57(2), 251-302.
25.
Kopp, S. W., & Bang, H. K. (2000). Benefit and risk information in prescription drug advertising: Review of empirical studies and marketing implications. Health Marketing Quarterly, 17(3), 39-56.
26.
Lindor, N. M., Sloan, J., Goldberg, R., Bowen, D., Nigon, S., Roche, A., et al. (2004). Colorectal tumour microsatellite instability test results: Perspectives from patients. Hereditary Cancer in Clinical Practice, 2(2), 69-75.
27.
Linn, L. S., & Davis, M. S. (1972). Physicians’ orientation toward the legitimacy of drug use and their preferred source of new drug information. Social Science & Medicine, 6(2), 199-203.
28.
Malone, K. E., Daling, J. R., Thompson, J. D., O’Brien, C. A., Francisco, L. V., & Ostrander, E. A. (1998). BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history. Journal of the American Medical Association, 279(12), 922-929.
29.
Mintzes, B., Barer, M. L., Kravitz, R. L., Kazanjian, A., Bassett, K., Lexchin, J., et al. (2002). Influence of direct to consumer pharmaceutical advertising and patients’ requests on prescribing decisions: Two site cross sectional survey. BMJ, 324(7332), 278-279.
30.
Nelson, C. P., & Bloom, D. A. (2001). Sales and science: Changing patterns of pharmaceutical and medical device advertising in peer reviewed urology publications, 1975-2000. Journal of Urology, 166(6), 2317-2320.
31.
Newman, B., Mu, H., Butler, L. M., Millikan, R. C., Moorman, P. G., & King, M. C. (1998). Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. Journal of the American Medical Association, 279(12), 915-921.
32.
Niccol, A. (Writer/Director). (1997). Gattaca [Motion picture]. United States: Columbia TriStar Pictures.
33.
Quaid, K. A., & Morris, M. (1993). Reluctance to undergo predictive testing: The case of Huntington disease. American Journal of Medical Genetics, 45, 41-45.
34.
Robinson, A. R., Hohmann, K. B., Rifkin, J. I., Topp, D., Gilroy, C. M., Pickard, J. A., et al. (2004). Direct-to-consumer pharmaceutical advertising: Physician and public opinion and potential effects on the physician-patient relationship. Archives of Internal Medicine, 164(4), 427-432.
35.
Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Frank, R. G., & Epstein, A. M. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346(7), 498-505.
36.
Services, United States Department of Health and Human Services. (2005). U.S. Surgeon general’s family history initiative. Retrieved April, 2005, from http://www.hhs.gov/familyhistory/
37.
Spiller, L. D., & Wymer, W. W., Jr. (2001). Physicians’ perceptions and uses of commercial drug information sources: An examination of pharmaceutical marketing to physicians. Health Marketing Quarterly, 19(1), 91-106.
38.
Stryer, D., & Bero, L. A. (1996). Characteristics of materials distributed by drug companies. An evaluation of appropriateness. Journal of General Internal Medicine, 11(10), 575-583.
39.
Wang, C., Gonzalez, R., Milliron, K. J., Strecher, V. J., & Merajver, S. D. (2005). Genetic counseling for BRCA1/2: A randomized controlled trial of two strategies to facilitate the education and counseling process. American Journal of Medical Genetics Part A, 134(1), 66-73.
40.
Wilkes, M. S., Doblin, B. H., & Shapiro, M. F. (1992). Pharmaceutical advertisements in leading medical journals: Experts’ assessments. Annals of Internal Medicine, 116(11), 912-919.
